EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce that the “Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomised study evaluating the clinical utility of the 70-gene signature (MammaPrint®) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes” will be presented during the AACR Annual Meeting 2016 (16 – 20 April, New Orleans, Louisiana, USA – www.aacr.org).
MINDACT is the first prospective randomised controlled clinical trial of a breast cancer recurrence genomic assay with Level 1A clinical evidence. It is also the first prospective translational research study of this magnitude in breast cancer to report the results of its primary objective.
AACR has identified MINDACT as newsworthy and will include it in the conference’s official media relations programme. On Monday, April 18, a press conference is scheduled at 8:30 am CDT, during which Professor Martine Piccart, one of the three principal investigators of MINDACT, as well as Professor Laura van ‘t Veer, Leading Scientist and developer of the 70-gene signature, will be available to answer questions about the trial design and the potential importance of its results.
The actual presentation of MINDACT results will be made by Professor Piccart in the Clinical Trials Plenary Session taking place soon thereafter:
Session Title: Transformative Clinical Trials in Breast Cancer
Session Start Time: Monday, April 18, 2016, 10:30 AM
Session End Time: Monday, April 18, 2016, 12:30 PM
Location: La Nouvelle Orleans Ballroom, Morial Convention Center
CME Status: CME-Designated Session
Once MINDACT study results have been made public, EORTC, BIG and Agendia will communicate them on their websites. For more information, please visit: